A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6

Authors: Hughes, Brett G.M., Guminski, Alexander, Bowyer, Samantha, Migden, Michael R., Schmults, Chrysalyne D., Khushalani, Nikhil I., Chang, Anne Lynn S., Grob, Jean-Jacques, Lewis, Karl D., Ansstas, George, Day, Fiona, Ladwa, Rahul, Stein, Brian N., Muñoz Couselo, Eva, Meier, Friedegund, Hauschild, Axel, Schadendorf, Dirk, Basset-Seguin, Nicole, Modi, Badri, Dalac-Rat, Sophie, Dunn, Lara A., Flatz, Lukas, Mortier, Laurent, Guégan, Sarah, Heinzerling, Lucie M., Mehnert, Janice M., Trabelsi, Sabiha, Soria-Rivas, Ainara, Stratigos, Alexander J., Ulrich, Claas, Wong, Deborah J., Beylot-Barry, Marie, Bossi, Paolo, Bugés Sánchez, Cristina, Chandra, Sunandana, Robert, Caroline, Russell, Jeffery S., Silk, Ann W., Booth, Jocelyn, Yoo, Suk-Young, Seebach, Frank, Lowy, Israel, Fury, Matthew G., Rischin, Danny

Source: In Journal of the American Academy of Dermatology January 2025 92(1):68-77

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Authors: Weichenthal, Michael ^{a, ⁎}, Ellebaek, Eva ^b, Mangana, Joanna ^c, Asher, Nethanel ^d, Gavrilova, Iva ^e, Kandolf, Lidija ^f, Ugurel, Selma ^g, Hausschild, Axel ^a, Meier, Friedegund ^h, Leiter, Ulrike ⁱ, Livingstone, Elisabeth ^g, Gebhardt, Christoffer ^j, Gutzmer, Ralf ^k, Ruhlmann, Christina H. ^l, Mahncke-Guldbrandt, Louise ^m, Haslund, Charlotte A. ⁿ, Kopec, Sylwia ^o, Teterycz, Paweł ^p, Bender, Marc ^q, Poudroux, Wilfried ^r, Muñoz-Couselo, Eva ^s, Berciano-Guerrero, Miguel-Angel ^t, Shalamanova, Gergana ^u, DePalo, Danielle K. ^v, Brozić, Jasmina Marić ^w, Chiarion-Sileni, Vanna ^x, Arance, Anna ^y, Ziogas, Dimitrios ^z, Robert, Caroline ^aa, van de Velde, Anthonie Obik ^ab, Gassama, Awa Aminata ^ac, Shapira, Ronnie ^ad, BenBetzalel, Guy ^ad, Grynberg, Shirly ^ad, Ramelyte, Egle ^c, Bertoldo, Fabio ^c, DelPrete, Valerio ^c, Gaudy-Marqueste, Caroline ^ae, Mohr, Peter ^af, Dummer, Reinhard ^c, Ascierto, Paolo A. ^ag, Gogas, Helen ^z, Espinosa, Enrique ^ah, Lebbé, Celeste ^ai, Rutkowski, Piotr ^o, Haanen, John ^aj, Schadendorf, Dirk ^g, Svane, Inge Marie ^b

Source: In European Journal of Cancer 2 May 2025 220

Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

Authors: Mirallas, Oriol, Martin-Cullell, Berta, Navarro, Víctor, Vega, Kreina Sharela, Recuero-Borau, Jordi, Gómez-Puerto, Diego, López-Valbuena, Daniel, Salva de Torres, Clara, Andurell, Laura, Pedrola, Anna, Berché, Roger, Palmas, Fiorella, Ucha, José María, Villacampa, Guillermo, Rezqallah, Alejandra, Sanz-Beltran, Judit, Bach, Rafael, Bueno, Sergio, Viaplana, Cristina, Molina, Gaspar, Hernando-Calvo, Alberto, Aguilar-Company, Juan, Roca, María, Muñoz-Couselo, Eva, Martínez-Martí, Alex, Alonso, Ada, Eremiev, Simeon, Macarulla, Teresa, Oaknin, Ana, Saura, Cristina, Élez, Elena, Felip, Enriqueta, Peñuelas, Ángeles, Burgos, Rosa, Pardo, Patricia Gómez, Garralda, Elena, Tabernero, Josep, Serradell, Sònia, Servitja, Sònia, Paez, David, Dienstmann, Rodrigo, Carles, Joan

Source: In The Lancet Regional Health - Europe November 2024 46

Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study

Authors: Riveiro-Barciela, Mar, Barreira-Díaz, Ana, Callejo-Pérez, Ana, Muñoz-Couselo, Eva, Díaz-Mejía, Nely, Díaz-González, Álvaro, Londoño, María-Carlota, Salcedo, Maria-Teresa, Buti, María

Source: Clinical gastroenterology and hepatology. 21(3):732-740

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183939326.0x000001&indx=1&recIds=ETOCvdc_100183939326.0x000001

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma

Authors: Wong, Selina K., Blum, Steven M., Sun, Xiaopeng, Da Silva, Inês P., Zubiri, Leyre, Ye, Fei, Bai, Kun, Zhang, Kevin, Ugurel, Selma, Zimmer, Lisa, Livingstone, Elisabeth, Schadendorf, Dirk, Serra-Bellver, Patricio, Muñoz-Couselo, Eva, Ortiz, Carolina, Lostes, Julia, Huertas, Roberto M., Arance, Ana, Pickering, Lisa, Long, Georgina V., Carlino, Matteo S., Buchbinder, Elizabeth I., Vázquez-Cortés, Leticia, Jara-Casas, Diego, Márquez-Rodas, Iván, González-Espinoza, Iván R., Balko, Justin M., Menzies, Alexander M., Sullivan, Ryan J., Johnson, Douglas B.

Source: European journal of cancer. 181:188-197

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100181179693.0x000001&indx=1&recIds=ETOCvdc_100181179693.0x000001

Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study

Authors: Schmid, Peter, Lipatov, Oleg, Im, Seock-Ah, Goncalves, Anthony, Muñoz-Couselo, Eva, Lee, Keun Seok, Tamura, Kenji, Testa, Laura, Witzel, Isabell, Ohtani, Shoichiro, Turner, Nicholas, Zambelli, Stefania, Harbeck, Nadia, Andre, Fabrice, Dent, Rebecca, Mejia, Jaime A., Zhou, Xuan, Haiderali, Amin, Nguyen, Allison Martin, Cortes, Javier, Winer, Eric P.

Source: In European Journal of Cancer December 2023 195

A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials

Authors: Hernando-Calvo, Alberto, Vila-Casadesús, Maria, Bareche, Yacine, Gonzalez-Medina, Alberto, Abbas-Aghababazadeh, Farnoosh, Lo Giacco, Deborah, Martin, Agatha, Saavedra, Omar, Brana, Irene, Vieito, Maria, Fasani, Roberta, Stagg, John, Mancuso, Francesco, Haibe-Kains, Benjamin, Han, Ming, Berche, Roger, Pugh, Trevor J., Mirallas, Oriol, Jimenez, Jose, Gonzalez, Nadia Saoudi, Valverde, Claudia, Muñoz-Couselo, Eva, Suarez, Cristina, Diez, Marc, Élez, Elena, Capdevila, Jaume, Oaknin, Ana, Saura, Cristina, Macarulla, Teresa, Galceran, Joan Carles, Felip, Enriqueta, Dienstmann, Rodrigo, Bedard, Philippe L., Nuciforo, Paolo, Seoane, Joan, Tabernero, Josep, Garralda, Elena, Vivancos, Ana

Source: In Med 13 October 2023 4(10):710-727

Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF^V600-mutant melanoma in Spain: the BECARE (GEM-2002) trial.

Authors: Soria, Ainara, Sanchez Mauriño, Pedro, Serrano Domingo, Juan José, García Galindo, Regina, Sequero, Silvia, Gutiérrez Sanz, Lourdes, Crespo, Guillermo, Díaz-Beveridge, Roberto, Puértolas, Teresa, López, Pedro, Fra Rodríguez, Joaquín, López Castro, Rafael, Aguayo, Cristina, Valdivia, Javier, Cunquero-Tomás, Alberto Jacobo, Benítez, Gretel, Ayala de Miguel, Pablo, Espinosa, Enrique, Muñoz-Couselo, Eva, Campos, Begoña

Source: Frontiers in Oncology; 2025, p1-11, 11p

Subject Terms: CLINICAL trials, IMMUNE checkpoint inhibitors, ADVERSE health care events, BRAIN metastasis, PATIENT safety, DACARBAZINE

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study.

Authors: Dent, Rebecca, Cortés, Javier, Park, Yeon Hee, Muñoz-Couselo, Eva, Kim, Sung-Bae, Sohn, Joohyuk, Im, Seock-Ah, Holgado, Esther, Foukakis, Theodoros, Kümmel, Sherko, Yearley, Jennifer, Wang, Anran, Nebozhyn, Michael, Huang, Lingkang, Cristescu, Razvan, Jelinic, Petar, Karantza, Vassiliki, Schmid, Peter

Source: Breast Cancer Research; 3/11/2025, Vol. 27 Issue 1, p1-12, 12p

Subject Terms: KILLER cells, PATHOLOGIC complete response, TRIPLE-negative breast cancer, RECEIVER operating characteristic curves, NEOADJUVANT chemotherapy

Loss of Lkb1 cooperates with Braf^V600E and ultraviolet radiation, increasing melanoma multiplicity and neural‐like dedifferentiation.

Authors: McGrail, Kimberley, González‐Sánchez, Elena, Granado‐Martínez, Paula, Orsenigo, Roberto, Ding, Yuxin, Ferrer, Berta, Hernández‐Losa, Javier, Ortega, Iván, Martín‐Caballero, Juan, Muñoz‐Couselo, Eva, García‐Patos, Vicente, Recio, Juan A.

Source: Molecular Oncology; Feb2025, Vol. 19 Issue 2, p329-343, 15p

Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse.

Authors: Martinez-Recio, Sergio, Molina-Pérez, Maria Alejandra, Muñoz-Couselo, Eva, Sevillano-Tripero, Alberto R., Aya, Francisco, Arance, Ana, Orrillo, Mayra, Martin-Liberal, Juan, Fernandez-Morales, Luis, Lesta, Rocio, Quindós-Varela, María, Nieva, Maria, Vidal, Joana, Martinez-Perez, Daniel, Barba, Andrés, Majem, Margarita

Source: Cancers; Jan2025, Vol. 17 Issue 1, p143, 14p

Subject Terms: MELANOMA prognosis, MELANOMA, CANCER relapse, IMMUNOTHERAPY, SCIENTIFIC observation, RETROSPECTIVE studies, DESCRIPTIVE statistics, MEDICAL records, ACQUISITION of data, RESEARCH, TUMOR classification, OVERALL survival

Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis.

Authors: Cerezuela-Fuentes, Pablo, Gonzalez-Cao, Maria, Puertolas, Teresa, Manzano, Jose Luis, Maldonado, Cayetana, Yelamos, Oriol, Berciano-Guerrero, Miguel A., Martin-Liberal, Juan, Muñoz-Couselo, Eva, Espinosa, Enrique, Drozdowskyj, Ana, Berrocal, Alfonso, Soria, Ainara, Marquez-Rodas, Ivan, Martin-Algarra, Salvador, Quindos, Maria, Puig, Susana

Source: Clinical & Translational Oncology; Jan2025, Vol. 27 Issue 1, p386-391, 6p

Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials

Authors: Matos, Ignacio, Villacampa, Guillermo, Hierro, Cinta, Martin-Liberal, Juan, Berché, Roger, Pedrola, Anna, Braña, Irene, Azaro, Analia, Vieito, Maria, Saavedra, Omar, Gardeazabal, Itziar, Hernando-Calvo, Alberto, Alonso, Guzmán, Galvao, Vladimir, Ochoa de Olza, Maria, Ros, Javier, Viaplana, Cristina, Muñoz-Couselo, Eva, Elez, Elena, Rodon, Jordi, Saura, Cristina, Macarulla, Teresa, Oaknin, Ana, Carles, Joan, Felip, Enriqueta, Tabernero, Josep, Dienstmann, Rodrigo, Garralda, Elena

Source: In European Journal of Cancer September 2021 155:168-178

Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1loss prevents BRAFV600E-induced growth arrest in melanocytes

Authors: McGrail, Kimberley, Granado-Martínez, Paula, Orsenigo, Roberto, Caratù, Ginevra, Nieto, Paula, Heyn, Holger, Ferrer, Berta, Hernández-Losa, Javier, Muñoz-Couselo, Eva, García-Patos, Vicenç, Recio, Juan A.

Source: Oncogene; 20250101, Issue: Preprints p1-17, 17p

Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer

Authors: Quintana, Ángela, Peg, Vicente, Prat, Aleix, Moliné, Teresa, Villacampa, Guillermo, Paré, Laia, Galván, Patricia, Dientsmann, Rodrigo, Schmid, Peter, Curigliano, Giuseppe, Muñoz-Couselo, Eva, Perez-García, José, Marti, Merce, Blanco-Heredia, Juan, Anjos, Carla dos, Vazquez, Miguel, De Mattos-Arruda, Leticia, Cortés, Javier

Source: In European Journal of Cancer May 2021 148:134-145

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Authors: Winer, Eric P ^*, Lipatov, Oleg, Im, Seock-Ah, Goncalves, Anthony, Muñoz-Couselo, Eva, Lee, Keun Seok, Schmid, Peter, Tamura, Kenji, Testa, Laura, Witzel, Isabell, Ohtani, Shoichiro, Turner, Nicholas, Zambelli, Stefania, Harbeck, Nadia, Andre, Fabrice, Dent, Rebecca, Zhou, Xuan, Karantza, Vassiliki, Mejia, Jaime, Cortes, Javier

Source: In The Lancet Oncology April 2021 22(4):499-511

Evaluation of the Effects of Repeat‐Dose Dabrafenib on the Single‐Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate)

Authors: Nebot, Noelia, Won, Christina S., Moreno, Victor, Muñoz‐Couselo, Eva, Lee, Dung‐Yang, Gasal, Eduard, Bouillaud, Emmanuel

Source: Clinical pharmacology in drug development. 10(9):1054-1063

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100128260097.0x000001&indx=1&recIds=ETOCvdc_100128260097.0x000001

COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study

Authors: Gonzalez-Cao, Maria, Carrera, Cristina, Rodriguez Moreno, Juan Francisco, Rodríguez-Jiménez, Pedro, Basa, Mónica Antoñanzas, Ochoa, Rosa Feltes, Puertolas, Teresa, Muñoz-Couselo, Eva, Manzano, José Luis, Marquez-Rodas, Ivan, Martín-Liberal, Juan, Soria, Ainara, Criado, Pilar Lopez, Garcia-Castaño, Almudena, Boada, Aram, Ayala de Miguel, Pablo, Puig, Susana, Crespo, Guillermo, Fra, Pablo Luna, Zamora, Cristina Aguayo, Rodríguez, Marta Feito, Valles, Lara, Drozdowskyj, Ana, Maldonado-Seral, Cayetana, Gardeazabal, Jesús, Villalobos, Laura, Rosell, Rafael, Fernandez-Morales, Luis Antonio, Rodrigo, Alberto, Viteri, Santiago, Provencio, Mariano, Berrocal, Alfonso

Source: Journal of the American Academy of Dermatology. 84(5):1412-1415

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100182463006.0x000001&indx=1&recIds=ETOCvdc_100182463006.0x000001

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.

Authors: Cohen, Graham, Rapoport, Bernardo, Chan, Sze W., Ruff, Paul, Arance, Ana, Mujika Eizmendi, Karmele, Houghton, Baerin, Brown, Michael P., Zielinski, Robert M., Muñoz Couselo, Eva, Lyle, Megan, Anderson, James R., Jain, Lokesh, de Alwis, Dinesh, Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Jacobs, Conrad

Source: PLoS ONE; 11/12/2024, Vol. 19 Issue 11, p1-13, 13p

Subject Terms: ADVERSE health care events, PROGRESSION-free survival, PEMBROLIZUMAB, PHARMACOKINETICS, MELANOMA

SEOM-GEM clinical guidelines for cutaneous melanoma (2023).

Authors: Márquez-Rodas, Iván, Muñoz Couselo, Eva, Rodríguez Moreno, Juan F., Arance Fernández, Ana Mª, Berciano Guerrero, Miguel Ángel, Campos Balea, Begoña, de la Cruz Merino, Luis, Espinosa Arranz, Enrique, García Castaño, Almudena, Berrocal Jaime, Alfonso

Source: Clinical & Translational Oncology; Nov2024, Vol. 26 Issue 11, p2841-2855, 15p